- Immunization for all patients without evidence of varicella immunity:
- Adults an >13 years: SC 0.5mL *2 doses 4-8 weeks apart
- 12 months- 12 years: SC 0.5mL *1 at 12-15 months, then 0.5mL *1 at 4-6 years
Injection: >103.3 PFUs/0.5mL
PFU=plaque forming units
None remarkable
Viral vaccine
It stimulates active immunity to disease caused by varicella-zoster virus. It conveys active immunity via stimulation of production of endogenously produced antibodies
- Injection site reaction
- Fever
- Varicella-like rash
- URI symptoms
- Irritability
- Headache
- Hypersensitivity to gelatin, neomycin or any component of the vaccine
- Pregnancy
- HIV: CD4+ count <200 cells/mcL
- Immunocompromised patients
- Acute febrile illness
- Immunocompromised patients
- Active untreated TB infection
- Patients receiving immunosuppressive therapy including immunosuppressive doses of corticosteroids
- Abatacept
- Abemaciclib
- Abrocitinib
- Acalabrutinib
- Adalimumab
- Aldesleukin
- Alemtuzumab
- Anakinra
- Anifrolumab
- Anti-thymocyte globulin
- Aspirin
- Axicabtagene ciloleucel
- Azacitidine
- Azathioprine
- Balsalazide
- Baricitinib
- Basiliximab
- Belatacept
- Belimumab
- Bendamustine
- Betamethasone
- Bismuth subsalicylate
- Blinatumomab
- Bortezomib
- Brentuximab vedotin
- Brexucabtagene autoleucel
- Brodalumab
- Budesonide
- Budesonide rectal
- Busulfan
- Cabazitaxel
- Canakinumab
- Capecitabine
- Carboplatin
- Carfilzomib
- Carmustine
- Certolizumab pegol
- Chlorambucil
- Ciltacabtagene autoleucel
- Cisplatin
- Cladribine injection
- Cladribine oral
- Clofarabine
- Copanlisib
- Corticotropin
- Cortisone
- Cyclophosphamide
- Cyclosporine
- Cytarabine
- Dacarbazine
- Dactinomycin
- Daratumumab
- Dasatinib
- Daunorubicin
- Decitabine
- Deflazacort
- Dexamethasone
- Dinutuximab
- Docetaxel
- Doxorubicin
- Dupilumab
- Durvalumab
- Duvelisib
- Eculizumab
- Efgartigimod alfa
- Elotuzumab
- Emapalumab
- Epirubicin
- Eribulin
- Etanercept
- Etoposide
- Everolimus
- Floxuridine
- Fludarabine
- Fludrocortisone
- Fluorouracil
- Gemcitabine
- Gemtuzumab ozogamicin
- Golimumab
- Guselkumab
- Hydrocortisone
- Hydroxyurea
- Ibritumomab tiuxetan
- Ibrutinib
- Idarubicin
- Idecabtagene vicleucel
- Idelalisib
- Ifosfamide
- Inebilizumab
- Infliximab
- Inotuzumab ozogamicin
- Irinotecan
- Isatuximab
- Ixabepilone
- Ixekizumab
- Leflunomide
- Lenalidomide
- Lisocabtagene maraleucel
- Lomustine
- Loncastuximab tesirine
- Lymphocyte immune globulin, anti-thymocyte globulin
- Magnesium salicylate
- Melphalan
- Mercaptopurine
- Mesalamine
- Mesalamine rectal
- Methotrexate
- Methyl salicylate topical
- Methylprednisolone
- Mitomycin
- Mitoxantrone
- Mogamulizumab
- Mycophenolate mofetil
- Mycophenolic acid
- Natalizumab
- Nelarabine
- Obinutuzumab
- Ocrelizumab
- Ofatumumab
- Olsalazine
- Omacetaxine mepesuccinate
- Oxaliplatin
- Ozanimod
- Paclitaxel
- Panobinostat
- Pegcetacoplan
- Pentostatin
- Polatuzumab vedotin
- Pomalidomide
- Ponatinib
- Ponesimod
- Pralatrexate
- Prednisolone
- Prednisone
- Procarbazine
- Ravulizumab
- Regorafenib
- Rilonacept
- Risankizumab
- Rituximab
- Ruxolitinib
- Salsalate
- Sarilumab
- Satralizumab
- Secukinumab
- Selinexor
- Siltuximab
- Siponimod
- Sirolimus
- Sutimlimab
- Tacrolimus
- Tafasitamab
- Temozolomide
- Temsirolimus
- Teriflunomide
- Thioguanine
- Thiotepa
- Tildrakizumab
- Tisagenlecleucel
- Tocilizumab
- Tofacitinib
- Topotecan
- Tralokinumab
- Trastuzumab
- Triamcinolone
- Trolamine salicylate topical
- Umbralisib
- Upadacitinib
- Ustekinumab
- Vedolizumab
- Venetoclax
- Vinblastine
- Vincristine
- Vinorelbine
- Voclosporin
- Zanubrutinib
Drug Status
| Availability | Prescription only |
| Pregnancy | Category X |
| Breastfeeding | Use with caution |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Varilrix | FDC | Injection | 1’s | GSK Ltd | GSK Ltd |